Evidence map›Paper›PMID 40374864›Full record

ArticleAnnals of surgical oncology2025

Radiologic and Pathologic Response Evaluation After Neoadjuvant Chemotherapy for Primary Retroperitoneal Sarcoma: A Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) Collaboration.

Stijn J C van der Burg, Marco Fiore, Piotr Rutkowski, Markus Albertsmeier, Sylvie Bonvalot, Valerie P Grignol, Chandrajit P Raut, Ferdinando C M Cananzi, John E Mullinax, David E Gyorki and 10 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Stijn J C van der BurgDepartment of Surgery, Antoni van Leeuwenhoek Hospital (NKI-AVL), Netherlands Cancer Institute, Amsterdam, The Netherlands.
Marco FioreDepartment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Piotr RutkowskiDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Markus AlbertsmeierDepartment of General, Visceral and Transplantation Surgery, Ludwig-Maximilians-Universität, University Hospital, Munich, Germany.
Sylvie BonvalotDepartment of Surgery, Institut Curie, PSL University, Paris, France.
Valerie P GrignolDepartment of Surgery, The Ohio State UniversityWexner Medical Center, Columbus, OH, USA.
Chandrajit P RautDepartment of Surgery, Harvard Medical School, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA, USA.
Ferdinando C M CananziDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
John E MullinaxDepartment of Sarcoma, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
David E GyorkiDivision of Cancer Surgery, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia.
Elisabetta PennacchioliDivision of Melanoma, Sarcomas and Rare Tumors, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Samuel J FordInstitute of Cancer and Genomics, University of Birmingham, Birmingham, UK.
Carolyn NessimDepartment of Surgery, The Ottawa Hospital and Research Institute, University of Ottawa, Ottawa, ON, Canada.
Kenneth CardonaDepartment of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Dario CallegaroDepartment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Jacek SkoczylasDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Lars H LindnerDepartment of Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Alessandro GronchiDepartment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Winan J Van HoudtDepartment of Surgery, Antoni van Leeuwenhoek Hospital (NKI-AVL), Netherlands Cancer Institute, Amsterdam, The Netherlands. w.v.houdt@nki.nl.ORCID http://orcid.org/0000-0002-2303-3468
TransAtlantic Australasian Retroperitoneal Sarcoma Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundComsplete resection is the primary treatment for retroperitoneal sarcomas (RPS). The role of neoadjuvant chemotherapy (NACT) in improving oncologic outcomes is currently under investigation in the STRASS 2 trial. This study assessed the association between change in tumor size or pathologic response and oncologic outcomes.

methodsData were retrieved from the international Retroperitoneal Sarcoma Registry and included patients who had RPS treated with NACT between January 2017 and October 2020. The correlation between radiologic response (RECIST1.1), change in tumor size, pathologic response, and oncologic outcomes was evaluated. Binary logistic, Cox, and polynomial spline regression and log-rank tests were performed as statistical analyses.

resultsThe study enrolled 141 patients from 14 medical centers. The most common histologies were dedifferentiated liposarcoma (36.9 %) and leiomyosarcoma (34 %). At completion of NACT, 14.5 % of the patients, had a partial response (PR), 63.3 % had stable disease (SD), and 22.2 % had progressive disease (PD). The hazard ratio of PD after NACT for overall survival (OS) was 1.9 (95 % confidence interval [CI], 0.9-4.1). A linear trend was observed between tumor growth and death rate. At early radiologic evaluation during NACT, PD was significantly associated, with worse OS (HR, 5.4; 95 % CI, 1.1-25.3). Partial response was significantly correlated with ≥20 % fibrosis/hyalinization (odds ratio [OR], 5.6; 95 % CI, 1.1-29.0).

conclusionProgression in RPS on an early evaluation scan is associated with worse OS, and radiologic response is correlated with pathologic response based on fibrosis/hyalinization. A larger cohort is necessary for more significant associations between radiologic or pathologic response and oncologic outcomes.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyRetroperitoneal NeoplasmsSarcomaAdultAgedChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansLeiomyosarcomaMaleMiddle AgedPrognosisRegistriesRetrospective StudiesOncologic outcomesProgressive diseaseRadiologic responseRetroperitoneal sarcomaTumor size

Identifiers

PMID40374864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.